Question

A 58-year-old male with a 35 pack-year smoking history presents with progressive exertional dyspnea and chronic morning cough. Pre-bronchodilator spirometry shows FEV1 of 1.80 L (52% predicted) and FVC of 3.10 L (74% predicted), yielding an FEV1/FVC ratio of 0.58. Following administration of 400 mcg of inhaled albuterol, his FEV1 increases to 1.95 L (an 8.3% and 150 mL increase), and FVC increases to 3.25 L, with a post-bronchodilator FEV1/FVC ratio of 0.60. According to GOLD guidelines, which criterion establishes the definitive diagnosis of persistent airflow limitation?

Obstructivas

Question · Easy

Question

A 64-year-old male with severe COPD (FEV1 42% predicted) remains persistently breathless and suffered two moderate exacerbations over the past 8 months despite adherent dual bronchodilator therapy with tiotropium and olodaterol (LAMA/LABA). His complete blood count reveals a peripheral blood eosinophil count of 380 cells/uL (4.2%). He has no history of mycobacterial disease or recurrent pneumonia. What is the most appropriate next step in his pharmacological management?

Obstructivas

Question · Medium

Question

A 70-year-old male with advanced COPD (FEV1 31% predicted) is evaluated in a stable clinical state 3 months after an exacerbation. Arterial blood gas on ambient air at sea level shows pH 7.39, PaCO2 44 mmHg, and PaO2 53 mmHg (resting SaO2 87%). An echocardiogram reveals normal left ventricular function and an estimated pulmonary artery systolic pressure of 32 mmHg. What is the evidence-based recommendation regarding long-term oxygen therapy (LTOT)?

Obstructivas

Question · Medium

Question

A 60-year-old male with severe diffuse bronchiectasis experiences four acute infectious pulmonary exacerbations over the preceding year. Serial sputum cultures persistently grow Pseudomonas aeruginosa (> 10^7 CFU/mL). He continues daily chest physiotherapy and airway clearance. To reduce exacerbation frequency in patients with chronic Pseudomonas colonization, which maintenance pharmacological strategy is supported by high-quality evidence?

Obstructivas

Question · Medium

Question

A 36-year-old female with long-standing severe asthma presents with worsening cough productive of brown mucus plugs, recurrent wheezing, and episodic low-grade fevers. Chest CT reveals central, proximal bronchiectasis with upper lobe predominance. Total serum IgE is markedly elevated at 2,400 IU/mL, peripheral eosinophils are 950 cells/uL, and serum precipitins and specific IgE to Aspergillus fumigatus are strongly positive. What is the standard initial therapy for acute allergic bronchopulmonary aspergillosis (ABPA)?

Obstructivas

Question · Medium

Question

A 62-year-old male with a 40 pack-year smoking history and a childhood diagnosis of allergic asthma presents with exertional dyspnea and chronic productive cough. Spirometry demonstrates persistent airflow limitation (post-bronchodilator FEV1/FVC 0.62, FEV1 54% predicted) with a post-bronchodilator FEV1 increase of 16% and 260 mL. His peripheral eosinophil count is 420 cells/uL. He is considered to have features of Asthma-COPD Overlap (ACO). What is the mandatory core principle regarding his maintenance pharmacotherapy?

Obstructivas

Question · Medium

Question

A 68-year-old male presents with a 9-month history of worsening exertional breathlessness and a dry hacking cough. Physical examination reveals bilateral fine end-inspiratory 'Velcro-like' crackles at the lung bases and digital clubbing. High-resolution chest CT (HRCT) is performed. According to international ATS/ERS/JRS/ALAT guidelines, which combination of HRCT features defines a Definite Usual Interstitial Pneumonia (UIP) pattern?

Intersticiales

Question · Medium

Question

A 71-year-old male is diagnosed with idiopathic pulmonary fibrosis (IPF) based on multidisciplinary discussion confirming a typical UIP pattern on HRCT and exclusion of alternative etiologies. His FVC is 72% predicted and DLCO is 54% predicted. Pirfenidone is prescribed at a target dose of 801 mg three times daily (2403 mg/day). What is the primary mechanism of action and the most characteristic dermatological side effect of pirfenidone?

Intersticiales

Question · Easy

Question

A 72-year-old male with established idiopathic pulmonary fibrosis on pirfenidone presents to the emergency department with acute worsening of dyspnea, dry cough, and hypoxemia developing over the preceding 12 days. Chest CT angiography excludes pulmonary thromboembolism but demonstrates new bilateral diffuse ground-glass opacities and areas of consolidation superimposed on his pre-existing background basal reticulation and honeycombing. Echocardiogram shows normal left ventricular filling pressures. What is the clinical diagnosis and recommended initial therapeutic approach?

Intersticiales

Question · Hard

Question

A 41-year-old male with biopsy-proven thoracic sarcoidosis is monitored closely. Over the past 4 months, he developed complete atrioventricular heart block requiring temporary pacing, and cardiac MRI reveals patchy mid-myocardial delayed gadolinium enhancement in the basal septum and left ventricular lateral wall. Which statement represents the definitive guideline-directed management regarding systemic corticosteroid therapy in this scenario?

Intersticiales

Question · Medium

Question

A 45-year-old woman with diffuse cutaneous systemic sclerosis (SSc) presents for pulmonary evaluation. She has sclerodactyly, Raynaud phenomenon, and anti-topoisomerase I (anti-Scl-70) antibodies. Baseline pulmonary function tests reveal FVC 64% predicted and DLCO 48% predicted. High-resolution chest CT shows extensive bilateral ground-glass opacities with fine reticulation and traction bronchiectasis conforming to a cellular Non-Specific Interstitial Pneumonia (NSIP) pattern. According to the 2023 ATS SSc-ILD guideline, informed by the Scleroderma Lung Studies (SLS I/II), which first-line immunosuppressive agent is recommended for SSc-ILD?

Intersticiales

Question · Medium

Question

A 56-year-old male presents with a 6-week history of low-grade fever, dry cough, malaise, and mild dyspnea, which failed to improve despite two courses of empirical outpatient antibiotics for suspected community-acquired pneumonia. HRCT shows bilateral, patchy, non-segmental subpleural and peribronchovascular consolidations and ground-glass opacities, with a characteristic 'reverse halo sign' (atoll sign: central ground glass surrounded by a crescentic or complete ring of consolidation). Transbronchial biopsy demonstrates intra-alveolar plugs of loose organizing connective tissue (fibroblastic Mason bodies) extending into alveolar ducts. What is the diagnosis and standard first-line management?

Intersticiales

Question · Medium

Question

A 28-year-old male with a 12 pack-year smoking history presents with exertional dyspnea and a non-productive cough. He experienced a spontaneous pneumothorax 2 years ago. High-resolution chest CT reveals a combination of ill-defined centrilobular nodules, cavitary nodules, and bizarrely shaped, bilobed, thick- and thin-walled cysts with absolute sparing of the lung bases and costophrenic sulci. What is the most likely diagnosis, and what is the primary initial therapeutic intervention?

Intersticiales

Question · Medium

Question

A 34-year-old female presents with recurrent spontaneous pneumothoraces and exertional dyspnea. Physical examination is notable for hypomelanotic macules ('ash-leaf spots') and facial angiofibromas. High-resolution CT shows multiple round, regular, thin-walled air-filled cysts uniformly distributed throughout both lungs, without craniocaudal sparing. A pleural tap of a large left-sided effusion reveals milky fluid with triglycerides of 240 mg/dL (chylothorax). Serum VEGF-D level is elevated at 1,450 pg/mL. Which targeted pharmacological therapy is approved to stabilize lung function decline in this disorder?

Intersticiales

Question · Hard

Question

A 58-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) on background methotrexate and leflunomide is monitored over a 12-month period. Over this interval, she reports worsening dyspnea on minimal exertion, her absolute FVC declines by 7% predicted, and repeat HRCT confirms increased extent of reticulation and traction bronchiectasis. She fulfills consensus criteria for Progressive Pulmonary Fibrosis (PPF) in a non-IPF fibrosing ILD. Based on the INBUILD trial, which therapeutic intervention is indicated?

Intersticiales

Question · Hard

Loading more…